Anebulo Pharmaceuticals Inc ANEB

$0.43 +0.07 (20.64%)

Valuation

Market cap
14,683,000
Revenue TTM
$0
Net income TTM
$-8,480,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
21,400
Avg volume
120,658
Day's range
$0.35 – $0.49
Shares out
40,785,000
Stochastic %K
44%
Beta
-0.81
Analysts
Sell
Price target
$3.00

Price

Company profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unme...

Show more

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
512 598 0931
Website
https://www.anebulo.com
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, United States

Latest news

Stocktwits

Whiskey1679 Mar 1, 4:54 PM
Whiskey Penny Picks out tomorrow. Any great cheap oil, defense/drone type stocks? Hit me up!! Might pick 'em tomorrow morning!! AH Gainers/trending a bit: $ELPW $LRHC $ANEB $INUV $BGL
2 replies
focafoca99 Feb 28, 7:21 AM
$ANEB confirmed, delisted this Monday. to quote in OTC
0 replies
focafoca99 Feb 26, 10:59 PM
$ANEB should be delisted today, right?
0 replies
peepthestamp Feb 18, 4:15 PM
$ANEB
0 replies
BasisTrading Feb 17, 1:25 PM
$ANEB Pre-revenue biotech; early-stage.
0 replies
d_risk Feb 12, 10:41 PM
$ANEB - Anebulo Pharmaceuticals, Inc. - 10Q - Updated Risk Factors ANEB flags ongoing zero revenue, a $78M accumulated deficit, rising R&D spend for clinical trials, and uncertainty about securing funding, warning it may need to scale back operations and may never reach profitability even after going private. #Pharmaceuticals #R&DSpending #FinancialRisk #FundingUncertainty #OperationalScaling 🟢 Added 🟠 Removed https://d-risk.ai/ANEB/10-Q/2026-02-12
0 replies
Stockinvestor73 Feb 9, 3:49 PM
$ANEB Hoe low can it go?
0 replies
DipDiverPro Feb 9, 3:31 PM
$ANEB Biotech or pharmaceutical; name not standard, indicating high risk.
0 replies